Safety study for stem cell transplant after mogamulizumab
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tracks safety in adults who had a stem cell transplant after taking mogamulizumab. It looks at outcomes and side effects over time, helping doctors understand risks for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are enrolled/registered with CIBMTR (the blood and marrow transplant registry)
- You are 18 years old or older
- You have CTCL (cutaneous T-cell lymphoma) or ATLL (adult T-cell leukemia/lymphoma)
- You had an allogeneic stem cell transplant (alloHCT) starting in January 2012 or later
- You can give consent to take part in research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
This early-phase study tests a combination of “natural killer” immune cells and a medicine called mogamulizumab to treat certain skin lymphomas that have come back or did not respond. It may help your immune system better find and attack cancer cells.
This trial compares two drugs, ATLG and ATG, to see which one helps rebuild the immune system better after a stem cell transplant for blood cancer. It aims to improve recovery and reduce complications.
This trial is for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a half-matched donor. It compares two different doses of a medicine that helps prevent the donor cells from attacking the body (graft-versus-host disease).
This trial tests whether a drug called mogamulizumab can prevent adult T-cell leukemia/lymphoma in people who carry the HTLV-1 virus and have a high viral load. It is for patients who have not yet developed the blood cancer.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Hear when a new Cutaneous T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.